Form D · Biotechnology
Pandion Therapeutics, Inc.
Cambridge, MA · CIK 0001727943
Offering snapshot reported Jan 22, 2018 · SEC filing
- Reported sold
- $21.6M Offering amount: $57.6M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 22, 2018 | Initial | $21,599,627 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-303791
Source: Form D, filed Jan 22, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Coyle | Director, Executive |
| Alan Crane | Director |
| Vikas Goyal | Director |
| Mitchell Mutz | Director |
| Carlo Rizzuto | Director |
| Jo Viney | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Labcentral 700 Main Street, North
Cambridge, MA, 02139
Cambridge, MA, 02139